Screener
Sutro Biopharma STRO Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Sutro Biopharma in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Sutro Biopharma’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 4:30 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-224170
| Line item | Three Months Ended / March 31, 2026 | Three Months Ended / March 31, 2025 |
|---|---|---|
| General and administrative | 7,584 | 13,273 |
| Restructuring and related costs | 42 | 21,043 |
| Total operating expenses | 44,179 | 85,913 |
| Loss from operations | (29,656) | (68,514) |
| Interest income | 1,635 | 3,189 |
| Non-cash interest expense related to the sale of future royalties | (9,467) | (9,344) |
| Interest and other income (expense), net | (1,011) | (1,292) |
| Loss before provision for income taxes | (38,499) | (75,961) |
Item 1. Financial Statements.
FAQ
- What is Sutro Biopharma's operating income?
- Sutro Biopharma (STRO) reported operating income of -$29.66M in Q1 2026.
- How has Sutro Biopharma's operating income changed year-over-year?
- Sutro Biopharma's operating income increased by 56.7% year-over-year, from -$68.51M to -$29.66M.
- What is the long-term trend for Sutro Biopharma's operating income?
- Over 3 years (2021 to 2025), Sutro Biopharma's operating income has grown at a 17.1% compound annual growth rate (CAGR), from -$98.52M to -$158.37M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Sutro Biopharma's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude